Lifshitz & Miller Law Firm Announces Investigation of AcelRx Pharmaceuticals, Inc., Ambit Biosciences, Athlon Energy Inc., Li...

NEW YORK, Oct. 7, 2014 /PRNewswire/ --

AcelRx Pharmaceuticals, Inc.

Lifshitz & Miller  announces that a class action complaint was filed in the United States District Court for the Northern District of California, alleging that AcelRx Pharmaceuticals, Inc. ("ACRX") issued false and misleading statements between December 2, 2013 and September 25, 2014.  The complaint alleges among other things that: (a) the IFU for Zalviso were not designed to adequately address the risk of the inadvertent misplacement of tablets; and (b) ACRX had not submitted to the FDA sufficient data to support the shelf life of the product.

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at [phone] or by sending an e-mail including your contact information to: [e-mail].

Ambit Biosciences

Lifshitz & Miller announces an investigation into possible breaches of fiduciary duties in connection with the proposed sale of Ambit Biosciences ("AMBI") to Daiichi Sankyo Company, Ltd. in a transaction valued at approximately $15 per share or up to $410 million, including, one CVR entitling the holder to receive an additional cash payment of up to $4.50 for each share they own if certain commercialization related milestones are achieved.  

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at [phone] or by sending an e-mail including your contact information to: [e-mail].

Athlon Energy Inc.

Lifshitz & Miller announces an investigation into possible breaches of fiduciary duties in connection with the proposed sale of Athlon Energy Inc. ("ATHL") to Encana Corporation in a transaction valued at approximately $7.1 billion or $58.50 per share, as well as Encana assuming Athlon's $1.15 billion of senior notes.  

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at [phone] or by sending an e-mail including your contact information to: [e-mail].

LipoScience, Inc.

Lifshitz & Miller announces an investigation into possible breaches of fiduciary duties in connection with the proposed sale of LipoScience, Inc. ("LPDX") to Laboratory Corporation of America Holdings in a transaction valued at approximately $5.25 per share or $85.3 million.  

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at [phone] or by sending an e-mail including your contact information to: [e-mail].

Simplicity Bancorp, Inc.

Lifshitz & Miller announces an investigation into possible breaches of fiduciary duties in connection with the proposed sale of Simplicity Bancorp, Inc. ("SMPL") to HomeStreet, Inc. SMPL stockholders are expected to receive one share of HomeStreet common stock for each share owned of SMPL common stock.  

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at [phone] or by sending an e-mail including your contact information to: [e-mail].

TIBCO Software Inc.

Lifshitz & Miller announces an investigation into possible breaches of fiduciary duties in connection with the proposed sale of TIBCO Software Inc. ("TIBX") to Vista Equity Partners in a transaction valued at approximately $4.3 billion or $24.00 per share.  

For more information about our investigation, please contact Joshua M. Lifshitz, Esq. by telephone at [phone] or by sending an e-mail including your contact information to: [e-mail].

ATTORNEY ADVERTISING. © 2014 Lifshitz & Miller.  The law firm responsible for this advertisement is Lifshitz & Miller, 821 Franklin Avenue, Suite 209, Garden City, New York 11530, Tel: [phone].  Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact:
Joshua M. Lifshitz, Esq.
Lifshitz & Miller
Phone:  [phone]
Facsimile: 516-280-7376
Email: [e-mail]

SOURCE Lifshitz & Miller Law Firm

Copyright 2014 PR Newswire